The Pharmacological Management of Bone and Muscle Disorders
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 20 August 2024 | Viewed by 2491
Special Issue Editor
Interests: muscle; bone; osteosarcopenia; nutraceuticals; skeletal muscle metabolism; muscle atrophy treatment; osteoporosis treatment
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Skeletal muscles are dynamic tissues capable of adapting in response to a variety of signals. Skeletal muscles experience mass changes as a result of physical activity, metabolism, and hormones. Atrophy is defined as a decrease in the size of a tissue or organ due to a decrease in cell size caused by the loss of organelles, cytoplasm, and proteins. This complex process occurs in skeletal muscle as a consequence of a variety of stressors, including neural inactivity, mechanical unloading, inflammation, metabolic stress, and elevated glucocorticoid levels. Muscle mass, in turn, depends on protein turnover. Muscle atrophy occurs when the rate of protein degradation exceeds that of protein synthesis.
The integrity of bone tissue is also maintained by a delicate balance between bone resorption (by osteoclasts) and bone formation (by osteoblasts). During physiological aging or pathology, this balance is altered, and pharmacological treatment must be carried out in an attempt to restore the balance. Drugs capable of restoring this balance are valuable for the treatment of pathologies such as osteoporosis, Paget's disease, rheumatoid arthritis, or periodontal disease.
Much less attention has been paid to promoting bone formation with, for example, growth factors or hormones, an approach that would represent a valuable adjunctive therapy for patients receiving bone resorption inhibitors.
This Special Issue of Pharmaceuticals, entitled “The Pharmacological Management of Bone and Muscle Disorders”, focuses on the pharmacological treatment of bone and muscle diseases and will therefore cover recent advances in the treatment of such diseases, including muscle atrophy, osteoporosis, and osteosarcopenia.
This Special Issue aims to collect articles that will further our understanding of the molecular mechanisms involved in bone and muscle disorders and the potential of their associated drugs, natural products, growth factors, and hormones. Topics of interest include the development and characterization of novel pharmaceutical approaches. Experimental papers and review articles are both welcome.
Dr. Francesca Bosco
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- muscle
- bone
- osteosarcopenia
- nutraceuticals
- skeletal muscle metabolism
- pharmacological management
